(NASDAQ: EWTX) Edgewise Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.49%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.68%.
Edgewise Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast EWTX's revenue for 2026 to be $3,030,032,544, with the lowest EWTX revenue forecast at $3,030,032,544, and the highest EWTX revenue forecast at $3,030,032,544. On average, 3 Wall Street analysts forecast EWTX's revenue for 2027 to be $6,247,832,417, with the lowest EWTX revenue forecast at $4,172,922,944, and the highest EWTX revenue forecast at $10,025,620,180.
In 2028, EWTX is forecast to generate $20,519,569,765 in revenue, with the lowest revenue forecast at $8,709,449,794 and the highest revenue forecast at $31,544,532,553.